23andMe make another big hire to boost their therapeutic ambitions.

23andMe announced the appointment of Robert Gentleman as their new Vice President of Computational Biology. His role will be to further explore how 23andMe’s database can be leveraged for drug development. Dr. Gentleman joins the company having been Senior Diretor of Bioinformatics and Computational Biology at Genentech.

“Dr. Gentleman is a trailblazer in his field,” said Andy Page, president, 23andMe. “A scientist of his caliber coming to the company speaks volumes about the rigorous scientific foundation 23andMe has built and the unique opportunity our data set provides to identify significant genetic discoveries.”

On his appointment, Dr. Gentleman said “My hope is that my experience can help bring better treatments to market fast for the patients who need them most,” said Dr. Gentleman.  “I’m excited to have the opportunity to work with the 23andMe community so we can together find these great cures.  It is the commitment of the active 23andMe research community that enables this potentially groundbreaking venture.”

This is another big move from 23andMe following their appointment of Richard Scheller to head up the new therapeutics division. With more hires to follow, all eyes will be who will be next to join personal genetics company. The scale of their database is proving to be a powerful selling point.